BAYER AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.2 EUR | +0.83% |
|
+3.47% | -19.27% |
| Apr. 24 | German cabinet approves restricted use of herbicide glyphosate | RE |
| Apr. 24 | Dehoga: Challenging situation for company canteens | DP |
| Sales 2024 * | 47.18B 50.53B | Sales 2025 * | 48.08B 51.5B | Capitalization | 26.5B 28.38B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.08B 2.23B | Net income 2025 * | 3.17B 3.39B | EV / Sales 2024 * | 1.26 x |
| Net Debt 2024 * | 33.11B 35.46B | Net Debt 2025 * | 29.67B 31.78B | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
12.3
x | P/E ratio 2025 * |
8.3
x | Employees | 96,931 |
| Yield 2024 * |
0.41% | Yield 2025 * |
0.86% | Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bayer AG
More press releases
More news
| 1 day | -0.16% | ||
| 1 week | +2.74% | ||
| Current month | -5.14% | ||
| 1 month | +0.84% | ||
| 3 months | -17.33% | ||
| 6 months | -34.67% | ||
| Current year | -19.80% |
1 week
25.61
27.70
1 month
25.6128.94
Current year
24.9636.09
1 year
24.9660.81
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Managers | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
| Director of Finance/CFO | 54 | 18-04-25 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
| Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 67 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | - | |
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 27.14 | +0.65% | 978 461 |
| 24-04-24 | 26.97 | -1.37% | 2,710,724 |
| 24-04-23 | 27.34 | +0.11% | 3,055,329 |
| 24-04-22 | 27.32 | +3.76% | 4,999,901 |
| 24-04-19 | 26.32 | +0.32% | 4,224,860 |
Delayed Quote Xetra, April 24, 2024 at 11:35 am EDT
More quotes
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
2024-04-26
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
26.97
EUR
Average target price
37.05
EUR
Spread / Average Target
+37.37%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.80% | 28.31B | |
| +25.61% | 660B | |
| +25.87% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +7.09% | 219B | |
| -9.12% | 196B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- BAYN Stock
